Literature DB >> 17409287

Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis.

Robert R Langley1, Isaiah J Fidler.   

Abstract

The process of cancer metastasis is sequential and selective and contains stochastic elements. The growth of metastases represents the endpoint of many lethal events that few tumor cells can survive. Primary tumors consist of multiple subpopulations of cells with heterogeneous metastatic properties, and the outcome of metastasis depends on the interplay of tumor cells with various host factors. The findings that different metastases can originate from different progenitor cells account for the biological diversity that exists among various metastases. Even within a solitary metastasis of proven clonal origin, however, heterogeneity of biological characteristics can develop rapidly. The pathogenesis of metastasis depends on multiple interactions of metastatic cells with favorable host homeostatic mechanisms. Interruption of one or more of these interactions can lead to the inhibition or eradication of cancer metastasis. For many years, all of our efforts to treat cancer have concentrated on the inhibition or destruction of tumor cells. Strategies both to treat tumor cells (such as chemotherapy and immunotherapy) and to modulate the host microenvironment (including the tumor vasculature) should offer additional approaches for cancer treatment. The recent advances in our understanding of the biological basis of cancer metastasis present unprecedented possibilities for translating basic research to the clinical reality of cancer treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17409287     DOI: 10.1210/er.2006-0027

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  162 in total

1.  Selection of brain metastasis-initiating breast cancer cells determined by growth on hard agar.

Authors:  Lixia Guo; Dominic Fan; Fahao Zhang; Janet E Price; Ju-Seog Lee; Dario Marchetti; Isaiah J Fidler; Robert R Langley
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Finding the tumor copycat. Therapy fails, patients don't.

Authors:  Lee M Ellis; Isaiah J Fidler
Journal:  Nat Med       Date:  2010-09       Impact factor: 53.440

3.  Cancer: Genomics of metastasis.

Authors:  Joe Gray
Journal:  Nature       Date:  2010-04-15       Impact factor: 49.962

Review 4.  AACR centennial series: the biology of cancer metastasis: historical perspective.

Authors:  James E Talmadge; Isaiah J Fidler
Journal:  Cancer Res       Date:  2010-07-07       Impact factor: 12.701

Review 5.  Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Mol Aspects Med       Date:  2013-08-29

6.  Elevated proinflammatory cytokine IL-17A in the adjacent tissues along the adenoma-carcinoma sequence.

Authors:  Guanglin Cui; Hang Yang; Jianbo Zhao; Aping Yuan; Jon Florholmen
Journal:  Pathol Oncol Res       Date:  2014-05-25       Impact factor: 3.201

7.  In vivo photoswitchable flow cytometry for direct tracking of single circulating tumor cells.

Authors:  Dmitry A Nedosekin; Vladislav V Verkhusha; Alexander V Melerzanov; Vladimir P Zharov; Ekaterina I Galanzha
Journal:  Chem Biol       Date:  2014-05-08

8.  Overview of human primary tumorgraft models: comparisons with traditional oncology preclinical models and the clinical relevance and utility of primary tumorgrafts in basic and translational oncology research.

Authors:  David H Lum; Cindy Matsen; Alana L Welm; Bryan E Welm
Journal:  Curr Protoc Pharmacol       Date:  2012-12

Review 9.  Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis.

Authors:  M P Kim; S I Park; S Kopetz; G E Gallick
Journal:  Cell Tissue Res       Date:  2008-09-25       Impact factor: 5.249

10.  A multi-site metastasis-on-a-chip microphysiological system for assessing metastatic preference of cancer cells.

Authors:  Julio Aleman; Aleksander Skardal
Journal:  Biotechnol Bioeng       Date:  2018-12-31       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.